This Biotech Stock Could Be the Best Investment of the Decade

19.04.25 16:00 Uhr

Werte in diesem Artikel
Aktien

0,49 EUR 0,07 EUR 16,11%

Picking stocks with a relatively narrow timeframe in mind -- and with a particular performance expectation -- can be tricky. Most investors can distinguish between bad, good, and even-better investment prospects. But it's impossible to know exactly how well a stock will perform, or when it will perform well. That's why Warren Buffett's favorite holding period is simply "forever."However, every now and then, the proverbial planets line up. That is to say, it becomes clear that a company is on the cusp of massive and sustained growth, with its stock poised to follow suit.Iovance Biotherapeutics (NASDAQ: IOVA) is one such company right now, entering a decade of incredible growth. Here's why aggressive investors might want to use the stock's recent weakness as a buying opportunity.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Ausgewählte Hebelprodukte auf :be

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf :be

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: MotleyFool

Nachrichten zu :be AG Inhaber-Akt

Wer­bung